Anil Ramaswamy
Pediatric Endocrinology · Richmond, VANPI 1598859951
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $499 and has fallen 85.2% since, to $74 in 2025.
Across 66 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$152
- Abbott$128
- Insulet Corporation$108
- Lilly USA, LLC$98
- Dexcom, Inc.$76
- Medtronic$71
- plus $590 from 18 others
Across 6 payments — averaging $15,767 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$95K
What the payments were for
- Food & beverage$1,20899%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $152 |
| Abbott | 6 | $128 |
| Insulet Corporation | 4 | $108 |
| Lilly USA, LLC | 5 | $98 |
| Dexcom, Inc. | 4 | $76 |
| Medtronic(2 entities) | 5 | $71 |
| AbbVie | 3 | $66 |
| Tolmar Pharmaceuticals, Inc. | 4 | $64 |
| Tandem Diabetes Care, Inc. | 3 | $59 |
| Pfizer | 3 | $50 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Endo Pharmaceuticals Inc. | 2 | $39 |
| Rhythm Pharmaceuticals, Inc. | 2 | $32 |
| Biomarin Pharmaceutical Inc. | 1 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Sequel Med Tech, LLC | 1 | $23 |
| Lifescan, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| UCB, Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
How this compares
$1,222 in reported general payments places this provider in the 60th percentile of 36 pediatric endocrinology providers in Virginia.
Other pediatric endocrinology in Richmond
- Bryce NelsonRichmond$115K
- Edmond WickhamRichmond$2K
- Elna KochummenRichmond$1K
- Arti ShahRichmond$415
- Ladan Davallow GhajarRichmond$241
- Mareen ThomasRichmond$185
- Ashlyn CoxRichmond$162
- Jessica RadcliffeRichmond$134
- Leslie FergusonRichmond$51
- Craig RudlinRichmond$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.